The European Society of Human Reproduction and Embryology (ESHRE) 38th Annual Meeting

Milan, Italy 03 July 2022 - 06 July 2022

Does frozen embryo transfer up hypertension risk during pregnancy?

25 Sep 2022 by

The risk of hypertensive disorders in pregnancy (HDP) is increased following assisted reproductive technology (ART) using frozen embryo transfer (FET) compared with after fresh embryo transfer or natural conception, according to results of a study presented at ESHRE 2022.

Does frozen embryo transfer up hypertension risk during pregnancy?

25 Sep 2022

Probiotic supplement has no effect on vaginal microbiome in women undergoing IVF

04 Sep 2022 by

A 10-day course of probiotics containing two strains of lactobacilli does not appear to improve vaginal microbiome quality in women planning to undergo in vitro fertilization (IVF), according to results of a recent study presented at ESHRE 2022.

Probiotic supplement has no effect on vaginal microbiome in women undergoing IVF

04 Sep 2022

Live birth after breast cancer may improve overall survival

22 Aug 2022 by

Women who become pregnant and have a live birth following a diagnosis of breast cancer may have better overall survival (OS) outcomes than those without live births post-cancer, according to a study presented at ESHRE 2022.

Live birth after breast cancer may improve overall survival

22 Aug 2022

Short GnRH antagonist protocol in ART may reduce ovarian hyperstimulation risk

15 Aug 2022 by

A large systematic review and meta-analysis of women undergoing assisted reproduction has shown that the use of short gonadotropin-releasing hormone (GnRH) antagonist protocols, compared with long GnRH agonist protocols, during controlled ovarian stimulation (COS) may reduce the risk of ovarian hyperstimulation syndrome (OHSS) while having no major impact on live birth rates.

Short GnRH antagonist protocol in ART may reduce ovarian hyperstimulation risk

15 Aug 2022

Relugolix-CT benefit for endometriosis-associated pain sustained through week 104

12 Aug 2022 by

Long-term combination therapy with relugolix plus oestradiol and norethindrone (relugolix-CT) shows sustained reductions in dysmenorrhoea and non-menstrual pelvic pain (NMPP) for up to 2 years in premenopausal women with endometriosis, according to the SPIRIT extension* study presented at ESHRE 2022.

Relugolix-CT benefit for endometriosis-associated pain sustained through week 104

12 Aug 2022

Similar asthma outcomes, but higher allergy rates, in ART-conceived children

11 Aug 2022 by

Children conceived through assisted reproductive technology (ART) showed similar asthma outcomes but had a higher risk of allergies and slightly altered lung function compared with those who were born after spontaneous conception, according to a study presented at ESHRE 2022.

Similar asthma outcomes, but higher allergy rates, in ART-conceived children

11 Aug 2022

BTX relieves endometriosis-associated chronic pelvic pain

29 Jul 2022 by

The administration of onabotulinumtoxinA (BTX) led to relief of pain and spasm in premenopausal women with persistent pelvic pain due to endometriosis, a study presented at ESHRE 2022 has shown.

BTX relieves endometriosis-associated chronic pelvic pain

29 Jul 2022

Does COVID-19 impair male fertility?

28 Jul 2022 by

A number of studies presented at ESHRE 2022 revealed conflicting findings regarding the effect of COVID-9 on male fertility. While some studies say it does, other data appear to state otherwise.

Does COVID-19 impair male fertility?

28 Jul 2022